Phase 2 Tics Clinical Trials
15 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–15 of 15 trials
Recruiting
Phase 2
Sodium Bicarbonate and Mitochondrial Energetics in Persons With CKD
Insulin ResistanceChronic Kidney DiseasesFatigue+4 more
University of California, Davis80 enrolled2 locationsNCT04984226
Recruiting
Phase 2Phase 3
Comparison of the Pharmacokinetics (PK) and Pharmacodynamics (PD) Biosimilarity of Proposed Biosimilar/Interchangeable Rapid-Acting Insulin Aspart (I004) and NovoLog® After Single-Dose Subcutaneous Administration to Healthy Volunteers
PharmacokineticsPharmacodynamicsInsulin Aspart
Amphastar Pharmaceuticals, Inc.60 enrolled1 locationNCT07560150
Recruiting
Phase 2
CBIT+TMS R33 Phase
Tourette SyndromeTics
University of Minnesota60 enrolled1 locationNCT06678737
Recruiting
Phase 2Phase 3
Managing Agitated Delirium With Neuroleptics and Anti-Epileptics as a Neuroleptic Sparing Strategy
DeliriumEpilepticsNeuroleptics
M.D. Anderson Cancer Center42 enrolled1 locationNCT05431595
Recruiting
Phase 1Phase 2
Phase1/2a Study for IPG7236 in Patients With Advanced Solid Tumors
Safety IssuesTolerabilityPharmacokinetics
Nanjing Immunophage Biotech Co., Ltd196 enrolled7 locationsNCT05142592
Recruiting
Phase 2
Stage II-IIIa Urothelial Cancer Randomizing Pre-operative Nivolumab With or Without Relatlimab
NeoplasmsNeoplasms by SiteUrinary Bladder Neoplasm+8 more
The Netherlands Cancer Institute90 enrolled9 locationsNCT06237920
Recruiting
Phase 2Phase 3
Pancreatic Cancer Diagnosis With FAPI-PET Imaging
Pancreatic CancerFAPIPositron Emission Tomography+5 more
Turku University Hospital100 enrolled1 locationNCT07098598
Recruiting
Phase 1Phase 2
Autologous Transplantation Combined With BCMA CAR-T in the Treatment of UHR-MM
Plasma Cell LeukemiaUltra High Risk mm (uhr-mm), 18-70 Years Old, Suitable for ASCT. And Meet Any of the Following uhr-mm DefinitionsCytogenetics Ultra High Risk+4 more
Institute of Hematology & Blood Diseases Hospital, China50 enrolled1 locationNCT07109323
Recruiting
Phase 1Phase 2
Opioid Drug Interaction Study
Drug Kineticsdrug interactions
Shanna Babalonis, PhD25 enrolled1 locationNCT06757140
Recruiting
Phase 2
Probiotics in Advanced Urothelial Carcinoma
ImmunotherapyAdvanced Urothelial CarcinomaProbiotics
Sun Yat-sen University222 enrolled3 locationsNCT06904573
Recruiting
Phase 2Phase 3
Rickettsia Clearance Study
Infectious DiseaseTherapeutics
Lao-Oxford-Mahosot Hospital Wellcome Trust Research Unit72 enrolled2 locationsNCT05972772
Recruiting
Phase 2
Synbiotics and Fecal Microbiota Transplantation to Treat Non-Alcoholic Steatohepatitis
Intestinal microbiomeNon-Alcoholic Fatty Liver DiseaseNon Alcoholic Steatohepatitis+6 more
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)48 enrolled1 locationNCT05821010
Recruiting
Phase 2
Topical Oxybutynin for Treatment of Hyperidrosis: Local or Systemic Effect?
Skin DiseasesHyperhidrosisOxybutynin+4 more
Samantha Rodrigues Camargo Neves de Moura17 enrolled1 locationNCT05102396
Recruiting
Phase 2
CELECOXIB Plasma and Cerebral Spinal Fluid Pharmacokinetics in Children
Pharmacokinetics of Celecoxib in Children
Children's Hospital of Eastern Ontario65 enrolled1 locationNCT01344200
Not Yet Recruiting
Phase 2
Multiple-dose pharmacokinetics and ex vivo pharmacodynamics of the fixed-dosed artemisinin based combination therapies (ACTs) of the antimalarial drugs Artequick (artemisinin-piperaquine) and Coarsucam (artesunate-amodiaquine) in healthy male Vietnamese volunteers
Characterization of the pharmacokinetics (absorption, metabolism, distribution and elimination) of the components of the antimalarial drugs Artequick and Coarsucam in healthy Vietnamese volunteers will provide important data for dose optimization and measurement of interindividual variability in plasma drug concentrations.
Australian Department of Defence44 enrolled1 locationACTRN12609000846224